IBRH3AU Biorepository Specimen Inventory

The table below represents an aggregate of samples available at the IBRH3AU Biorepository and the Associated studies, the resulting publications from each study and the name(s) of the funder(s), An integrated application for better report generation mechanism is coming soon. Researchers interested in materials are encouraged to Contact Us or fill a data access form.

Study Description Publications Specimen Type Funder
Parallel Comparison of Tenofovir and Emtricitabine/tenofovir Pre-Exposure Prophylaxis to prevent HIV-1 Acquisition with in Discordant Couples.

Design: Phase III, Multi site, Randomized, double-blind, placebo controlled trial.

Population: Heterosexual HIV-discordant couples. The HIV-1 uninfected partners were either male or female and not chronically infected with hepatitis B. At the time of study screening the HIV-1 infected partner were had a CD4 count>=250 cells/mm3.

Study Size: 3900 HIV-1 seronegative partners within HIV-1 dicordant couples(1300 in each treatment arm)

Study agents: Tenofovir disoproxil fumarate and emtricitabine.

» 4560 Whole Blood
» 12020 Serum
» 13564 Plasma
The Bill and Melinda Gates Foundation
Phase III Multi-site, randomized, double-blind, placebo-controlled, trial in which participants undergo treatment and follow-up for a maximum of twenty four month.

Design: Phase III Multi-site, randomized, double-blind, placebo-controlled, trial in which participants undergo treatment and follow-up for a maximum of twenty four month.

Population: Heterosexual HIV-discordant couples in which the HIV-Infected partner also is infected with HSV-2 and has a CD4 cell count of atleast 250cells/mm3 at screening.

Study Size: 3000 couples(1500 in each treatment arm). Final sample size determined by the number of end points.

Treatment Regimen: The HIV-Infected partner was assigned at random in a 1:1 ratio to either 400mg acyclovir or matching placebo taken orally twice daily.

Follow-up: for a maximum of 24 months

» 9120 Serum
» 1016 Plasma
The Bill and Melinda Gates Foundation
Multi-site, prospective, observational cohort. During Stage 1, the study was conducted in parallel with the Phase III Randomized Trial of HSV-2 Suppression to Prevent HIV Transmission among HIV-Discordant Couples.

Design: Multi-site, prospective, observational cohort. Study recruitment occurred in two stages. During Stage 1, the study was conducted in parallel with the Phase III Randomized Trial of HSV-2 Suppression to Prevent HIV Transmission among HIV-Discordant Couples and recruited couples who were ineligible to participate in that trial. After the phase III trial completed its enrollment, Stage 2 of the observational study recruited all willing HIV-discordant couples.

Population: Heterosexual HIV-discordant couples were recruited for this study. During Stage 1, couples included those who were ineligible to enroll in the clinical trial, in most cases because the HIV-infected partner is uninfected with HSV-2 or has a CD4 cell count ?250 cells/mm3 at screening. The sole exclusion criterion was current use of antiretroviral therapy by the HIV-infected partner. Couples were recruited from two study sites participating in phase III trial.

Study Size was 650 couples and Couples were followed quarterly for 12 months.

1. Acyclovir and Transmission of HIV-1 from Persons Infected with HIV-1 and HSV-2
2. Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial.
» 4420 Plasma ACD
» 4365 Serum
» 3072 Whole Blood Spots ACD
» 2052 BV slide Methanol Fixed
The Bill and Melinda Gates Foundation
Background: Up to 40% of HIV-infected individuals receiving Highly Active Antiretroviral Therapy (HAART) have poor CD4+ T-cell recovery. The role of natural killer (NK) cells in immune recovery during HAART is not well understood. We described the profiles of NK cell subsets and their expression of activating receptor, NKG2D and cytotoxicity receptor NKp46 among suboptimal immune responders to despite four years of suppressive HAART. 1. High CD56++CD16- natural killer (NK) cells among suboptimal immune responders after four years of suppressive antiretroviral therapy in an African adult HIV treatment cohort
2. CD4 T-cell Activation and Reduced Regulatory T-cell Populations are Associated with Early Development of Cataracts among HIV-infected Adults in Uganda
» 2097 PBMCs
» 2000 Plasma
The Belgian Government & Wellcome Trust

Study Design: The study was conducted using cross-sectional design. The design is appropriate for estimating the prevalence of LTBI.

Study setting: The study was conducted at the Baylor college of medicine-Bristol Meyes Squibb Children's Clinical Centre of excellence at Mulago Hospital Kampala Uganada(Bayolor Uganda). The clinic is responsible for HIV-Infected and HIV-Exposed children aged 6weeks and 18years with an active service population of about 4200 HIV infected children.

It operates comprehensive clinical care and HIV screening clinic Five days a week. Routine TB screening using TST is done for all newly diagnosed HIV positive children and all children suspected to have TB. A skin reaction (Induration) of 5mm or more in diameter is considered positive. All children are then investigated for active TB with chest X-ray, Microscopy and culture where necessary.

Study population: the population was HIV infected children aged 2months to 14 (Inclusive) years attending Baylor college of medicine-Bristol Meyes Squibb Children's Clinical Centre of excellence at Mulago Hospital Kampala Uganda (Bayolor Uganda).

1. Evaluation of the T-Spot.TB Test in the Diagnosis of Latent Tuberculosis Infection in HIV_Infected Children in Uganda » 2097 PBMCs
» 2000 Plasma
AIDS International Training and Research Program (AITRP)